|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-21
|
$581,591
|
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of macroH2A variants in cancer and senescence
|
5R01CA155232-08
|
$382,013
|
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
5T32CA200561-04
|
$264,583
|
|
MICHLER, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-05
|
$666,396
|
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade
|
1R43CA228319-01
|
$299,794
|
|
CHEN, RIDONG
|
APT THERAPEUTICS, INC.
|
|
Stand and Move at Work: A Group-Randomized Trial
|
5R01CA198971-04
|
$582,484
|
|
BUMAN, MATTHEW
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-04
|
$492,377
|
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Charge sensitive optical detection for high-throughput study of small molecules
|
5R33CA202834-03
|
$378,392
|
|
TAO, NONGJIAN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
TREM-1 and Its Implications to Cancer
|
5R01CA172230-05
|
$315,400
|
|
HORUZSKO, ANATOLIJ
|
AUGUSTA UNIVERSITY
|
|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-03
|
$29,664
|
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock transcription factor HSF1 in tumoroginesis
|
5R01CA062130-23
|
$556,510
|
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
PNNL Proteome Characterization Center
|
5U24CA210955-03
|
$1,063,923
|
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-05
|
$826,500
|
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-05
|
$307,736
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Functional Genomics and Precision Therapy Testing for Langerhans Cell Histiocytosis
|
1F31CA228360-01
|
$44,524
|
|
BURKE, THOMAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
3R01CA190776-04S1
|
$116,456
|
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-20
|
$320,963
|
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancer
|
5R03CA212816-02
|
$79,250
|
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
5R01CA190467-04
|
$362,569
|
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Tumor Suppressor Localization and Function at the Peroxisome
|
5R01CA143811-10
|
$356,625
|
|
WALKER, CHERYL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Osteoclast-independent mechanisms of early-stage bone colonization of breast canc
|
5R01CA183878-05
|
$324,738
|
|
ZHANG, XIANG
|
BAYLOR COLLEGE OF MEDICINE
|
|
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
|
5U24CA210954-03
|
$973,045
|
|
ZHANG, BING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
5R01CA184792-04
|
$347,517
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
|
5U01CA214254-02
|
$1,020,224
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Cancer Metabolism Training Program
|
1T32CA221709-01A1
|
$201,444
|
|
ANN, DAVID
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-04
|
$388,875
|
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
MACROPHAGE-MEDIATED IMMUNOSURVEILLANCE IN CANCER
|
5R00CA201075-04
|
$248,912
|
|
FENG, MINGYE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Improving Patient-Centered Communication and Cancer Care
|
5R25CA174627-05
|
$264,960
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care
|
5R25CA217270-02
|
$310,771
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
5R01CA205247-02
|
$450,769
|
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-06
|
$515,038
|
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development
|
5K01CA184388-05
|
$98,360
|
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenetic damage in women living in LA food-desert zip codes
|
5R01CA220693-02
|
$700,834
|
|
SEEWALDT, VICTORIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combined breast MRI/biomarker strategies to identify aggressive biology
|
5U01CA189283-04
|
$663,841
|
|
SEEWALDT, VICTORIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-04
|
$398,025
|
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5R00CA188595-04
|
$249,000
|
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-05
|
$359,556
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-04
|
$1,041,188
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A National Curriculum in Cancer Genomics for Residents and Medical Students
|
5R25CA168544-07
|
$231,248
|
|
HASPEL, RICHARD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms of regulation by RNA in acute myeloid leukemia
|
5R35CA197697-04
|
$1,042,185
|
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Enhancer RNA-mediated Tumor Suppressor Gene Expression in Normal and Malignant Hematopoiesis
|
5K01CA222707-02
|
$114,242
|
|
TRINH, BON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
|
5R44CA203068-03
|
$993,966
|
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
5R01CA204231-02
|
$390,712
|
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
5R01CA196703-04
|
$404,888
|
|
CHIARLE, ROBERTO
|
BOSTON CHILDREN'S HOSPITAL
|
Total relevant funding to Autoimmune Diseases for this search: $9,318,773
|